Back

Refining risk stratification in hypertrophic cardiomyopathy: the role of late gadolinium enhancement and syncope in predicting adverse outcomes

1 September 2024 (07:55 - 08:50)
Organised by: Logo
Congress Presentation Part of: Novel insights into Brugada syndrome and hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Christopher Mann

Medical University of Vienna, Vienna (Austria)

7 More presentations in this session

Presentation thumbnail
Relationship between epicardial adipose tissue and ventricular fibrillation in Brugada syndrome by cardiac computed tomography analysis
Mr K. Yonezu (Yufu City, JP)
Abstract Slides Video
Presentation thumbnail
Prognostic parameters predict cardiac events in Brugada syndrome: a meta-analysis
Mr P. Pajareya (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Novel electric predictors of lethal arrhythmic event in patients with hypertrophic cardiomyopathy
Professor J. Choi (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Prevalence of cardiovascular comorbidities among hospitalized patients with hypertrophic cardiomyopathy and factors associated with a higher case-fatality rate
Doctor S. Shoar (Largo, US)
Abstract Slides Video
Presentation thumbnail
Nationwide trends in utilization and safety of ventricular arrythmia ablation in patients with hypertrophic cardiomyopathy
Doctor G. Rozen (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Novel insights into Brugada syndrome and hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2024

1 September 2024 07:55 CET
You may be interested in
thumbnail
Congress Session
Prognostication in left ventricular hypertrophy: role of cardiac magnetic resonance imaging
thumbnail
Congress Presentation
Revisiting risk stratification in hypertrophic cardiomyopathy after the recent guidelines - LGE remains tough to beat
thumbnail
Congress Presentation
Prognostic role of the progression of late gadolinium enhancement in hypertrophic cardiomyopathy.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources